TianGang Yinuo Secures Tens of Millions of RMB in Pre-A+ Financing to Accelerate Clinical Translation of Innovative Immunotherapies

VCBeat learned exclusively that Hefei TG ImmunoPharma Co., Ltd. (TGI) announced the completion of a multi-million yuan pre-A+ round of financing. This round of financing was led by Hefei Industrial Investment Management, with participation from multiple investment institutions including CASSTAR, University of Science and Technology Silicon Valley Service Platform (Anhui) Co., Ltd., and Shandong Haichuang Ceyuan Investment Co., Ltd.This round of financing will provide important financial support for TGI's product development, advancing the clinical trials of core products and the development of new products, while accelerating the clinical translation of innovative immunotherapeutics.

TGI focuses on original innovation, emphasizes breakthroughs in transformative technologies, and is committed to the exploration and application of cutting-edge technologies. It continuously launches new products and technologies with independent intellectual property rights, occupying the innovative source of the pharmaceutical industry chain. The company has independently developed ABC-NKer.^®Platform and low-toxicity CD3 bispecific antibody platform facilitate the development of TCE, NKCE, immune checkpoint antibodies, and immune cytokine products. Based on a series of globally novel targets discovered independently, the company has developed more than 10 products across four major categories, all of which are either global first-in-class or best-in-class. Currently, TGI has obtained clinical trial approvals from the U.S. Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA) for three products (project codes: TGI-2, TGI-5, TGI-6). Among them, TGI-6 has already initiated Phase I clinical trials at Beijing Cancer Hospital and Shandong Cancer Hospital. To date, the dose-escalation trials for the first four dose groups have been successfully completed, with favorable and controllable safety data observed in the subjects.

Prof. Tian Zhigang, Academician of the Chinese Academy of Engineering & Academia Europaea, Founder of TGITGI stated: "After three years of hard work, TGI has developed a rich product pipeline, which is proceeding as expected. We are very grateful to the investment institutions that have consistently supported and paid attention to TGI. Their firm support during the capital winter not only shows high recognition of TGI but also reflects great expectations for China's innovative drug industry. The success of this pre-A+ round of financing will provide us with more sufficient financial support to accelerate the research and clinical transformation of core products in our pipeline. We will continue to focus on breakthroughs in core technologies, expedite the enrichment and upgrading of our product lines, and commit ourselves to developing original immunotherapy technologies and drugs, bringing more and better tumor immunotherapy drugs to patients."

The successful completion of this multi-million yuan pre-A+ round of financing not only marks significant ongoing progress by TGI in the research and development fields of TCE, NKCE, immune checkpoint antibodies, and immune cytokine drugs, but also provides strong financial support to accelerate the clinical translation of related drugs. This fully demonstrates the investment institutions' recognition of TGI's innovative technologies in the field of immunotherapy and their confidence in the company’s future development.

Hefei Industrial Investment Group's subsidiary, Hefei Industry Investment Capital, focuses on the strategic layout of our city's leading industries, with particular attention to sectors such as integrated circuits, flat panel displays, new energy vehicles, and biomedicine. The company manages 23 funds, with self-managed funds exceeding 10 billion yuan in scale, supporting over 200 projects cumulatively, with total investments surpassing 22 billion yuan. In the field of biomedicine, it has successively invested in companies like Haisen Bio (acquired Takeda assets), Hefei Qihao, Hainuo Technology, Kangnuo Pharmaceuticals, Jingze Bio, Ruishi Technology, Sale Pharmaceuticals, and Xingmu Bio, injecting capital momentum into the development of biomedicine enterprises in our city.

CASSTAR focuses on investing in "hard technology" and established its medical investment team in 2013, primarily targeting upstream and midstream R&D and production enterprises in the pharmaceuticals and medical device industry chain. To date, it has participated in the investment of over 40 early-stage companies. Its investment portfolio includes: Koka Life, Pulse Medical, Wushuang Medical, MicroLight, Chuan Shi Bio, DeepTrust Bio, and Zehui Bio, among others. CASSTAR's medical investments have actively explored the commercialization of academic research from universities. Among its invested companies, more than 10 were incubated from prestigious institutions such as the Chinese Academy of Sciences, Peking University, Tsinghua University, Westlake University, and Shanghai Jiao Tong University.

University of Science and Technology Silicon Valley focuses on the transformation of innovative achievements, incubation of innovative enterprises, catalysis of innovative industries, and optimization of the innovation ecosystem. It leverages the global alumni network of the University of Science and Technology of China and other universities and research institutes to gather worldwide innovative forces. It aims to become a "test field" for reforming the scientific and technological system and a "high-yield field" for high-tech industrial development, building an innovative valley full of vitality, leading the future, and renowned globally. As of the end of September 2024, the University of Science and Technology Silicon Valley area has welcomed 1,725 newly established technology enterprises, cumulatively gathering over 6,000 technology companies and scientific innovation service institutions, more than 60,000 various innovative and entrepreneurial talents, set up 12 domestic and overseas innovation centers, and aggregated over 200 funds with a total scale exceeding 230 billion yuan.

Haiyuan Capital is the earliest institution in Anhui Province to establish a professional government investment promotion fund and is the largest investment promotion fund management institution in the province. To date, Haiyuan Capital and its management team have cumulatively managed 10 funds, with a total subscribed scale of 5.94753 billion yuan, a total paid-in scale of 5.64248 billion yuan, and cumulative realized investment returns amounting to 3.11972 billion yuan. The Haiyuan Capital management team has directly led and completed 73 private equity investment projects, covering industries such as environmental protection, manufacturing, pharmaceuticals, chemicals, and technology, among which 15 projects have successfully achieved IPOs.

TGI is a biotech company founded by a research team led by Professor Tian Zhigang, an academician of both the Chinese Academy of Engineering and the European Academy of Sciences. The company is committed to the development of innovative target immunotherapeutics. With over 30 years of focus on anti-tumor immunity research, the team has spent the last decade leveraging the principles of the body’s natural anti-cancer immunity to discover new targets for cancer immunotherapy drugs and develop antibody-based immunotherapeutics. This enables original innovation and rapid translational development, positioning TGI at the forefront of global competition in large-molecule cancer immunotherapy drugs. TGI currently has a pipeline of more than 10 products, with indications covering solid tumors and autoimmune diseases.

TGI has a professional R&D base of nearly 6,000 square meters, including SPF-level animal laboratories, GMP-standard recombinant protein laboratories, BSL-2 biosafety laboratories, and an NK cell detection and analysis platform. It has successively won honors such as "Top 500 Hidden Unicorn Enterprises in China," "National Science and Technology SME," and "Specialized, Precise, Unique, and Innovative SME," with cumulative financing exceeding 200 million RMB. For more information, please visit www.tgimmunopharma.com.

Forward-Looking Statements

The information contained in this press release may include certain forward-looking statements, such as "may," "expected," "project," "plan," "show," "significant," "able," "have," "prospect," "expectation," or other variations or similar terms (collectively referred to as "forward-looking statements"). These statements inherently involve a certain degree of uncertainty and risk. We caution you not to place undue reliance on these forward-looking statements, as they are based solely on our current views, assumptions, expectations, estimates, forecasts, and understanding of future events as of the date of this press release. These statements are not absolute guarantees of the opinions expressed in this press release or the company’s future development, and will be influenced by potential risks, uncertainties, and other factors—some of which may be beyond the company's control—and are difficult to predict or effectively mitigate. Therefore, due to the future development and impact of changes in our business, competitive environment, political, economic, legal, and social conditions, actual results may differ significantly from the information contained in the forward-looking statements.

Based on this, our company and all employees shall not be obligated to: (1) correct or update any forward-looking statements contained in this press release; (2) assume any liability arising from the failure or inaccuracy of any forward-looking statements.